ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve share issuance for Lind note conversion

3. To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated February 23, 2023, by and among the Company and Lind Global Fund II, LP (“Lind”) , in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such convertible note and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants. For Against Abstain 18,835,192 115,688 529,236

2. To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023. For Against Abstain 19,388,899 86,207 5,010

1. To re-elect 11 directors to the Company’s board of directors (the “ Board ”), with such directors to serve until the 2024 annual meeting of shareholders. Name For Against Withheld Eugene Jiang 18,840,814 0 639,302 Norimi Sakamoto 18,796,356 0 683,760 Yen-Hsin Chou 18,833,715 0 646,401 Dr. Tsung-Shann (T.S.) Jiang 18,831,765 0 648,351 Hsin-Hui Miao 18,831,735 0 648,381 Yoshinobu Odaira 18,798,388 0 681,728 Dr. Tsang Ming Jiang 18,831,785 0 648,331 Dr. Chang-Jen Jiang 18,833,765 0 646,351 Che Wei Hsu 18,789,099 0 691,017 Shuling Jiang 18,855,080 0 625,036 Yu-Min (Francis) Chung 18,840,845 0 639,271